Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designted to know optimal dose of Ramosteron to control for chemotherapy induced nasea and vomoting (CINV)based on its pharmacokinetics, pharmacodynamic study and clinilcal parameters using Rhodes Index.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chonnam National University Hospital
• Treatments: Ramosetron

Criteria

Inclusion Criteria:

• Patients who recevied moderate emetogenic chemotherapy

• Age between 18-75

• ECOG PS 0-2

• Adequate organ fuction including bone marrow, liver and kidney

Exclusion Criteria:

• Gastrointestinal obstruction or carcinomatosis peritonei

• CNS metastasis or disability in CNS

• Intractable medical illness

• Pregnancy or inadequate contraception